Evidence map›Paper›PMID 36030465›Full record

ArticleThe British journal of dermatology2022

Giant congenital melanocytic naevus with a novel CUX1-BRAF fusion mutation treated with trametinib.

Vered Molho-Pessach, Stav Hartshtark, Sharon Merims, Michal Lotem, Nadia Caplan, Hila Alfassi, Alex Maly, Gal Goldstein, Rakefet Sidlik Muskatel

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Gene fusions in melanocytic lesions: an updated comprehensive review.Journal of pathology and translational medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Vered Molho-PessachDepartments of Dermatology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.ORCID 0000-0001-5346-611X
Stav HartshtarkDepartments of Dermatology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Sharon MerimsOncology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Michal LotemOncology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Nadia CaplanRadiology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Hila AlfassiPlastic Surgery, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Alex MalyPathology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Gal GoldsteinPediatric Hematology-Oncology; Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Rakefet Sidlik MuskatelPediatric Hematology-Oncology; Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.
Hebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Nevus, PigmentedSkin NeoplasmsHomeodomain ProteinsHumansMutationProto-Oncogene Proteins B-rafPyridonesPyrimidinonesRepressor ProteinsTranscription FactorsBRAF protein, humanCUX1 protein, humanHomeodomain ProteinsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesRepressor ProteinstrametinibTranscription Factors

Identifiers

PMID36030465
PMCPMC10087742
OpenAlexW4293388097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.